Back to Search
Start Over
Breast cancer survivorship care during the COVID-19 pandemic within an urban New York Hospital System.
- Source :
-
Breast (Edinburgh, Scotland) [Breast] 2021 Oct; Vol. 59, pp. 301-307. Date of Electronic Publication: 2021 Aug 04. - Publication Year :
- 2021
-
Abstract
- Purpose: To examine clinicodemographic determinants associated with breast cancer survivorship follow-up during COVID-19.<br />Methods: We performed a retrospective, population-based cohort study including early stage (Stage I-II) breast cancer patients who underwent resection between 2006 and 2018 in a New York City hospital system. The primary outcome was oncologic follow-up prior to and during the COVID-19 pandemic. Secondary analyses compared differences in follow-up by COVID-19 case rates stratified by ZIP code.<br />Results: A total of 2942 patients with early-stage breast cancer were available for analysis. 1588 (54%) of patients had attended follow-up in the year prior to the COVID-19 period but failed to continue to follow-up during the pandemic, either in-person or via telemedicine. 1242 (42%) patients attended a follow-up appointment during the COVID-19 pandemic. Compared with patients who did not present for follow-up during COVID-19, patients who continued their oncologic follow-up during the pandemic were younger (p = 0.049) more likely to have received adjuvant radiation therapy (p = 0.025), and have lower household income (p = 0.031) on multivariate modeling. When patients who live in Bronx, New York, were stratified by ZIP code, there was a modest negative association (r = -0.56) between COVID-19 cases and proportion of patients who continued to follow-up during the COVID-19 period.<br />Conclusion: We observed a dramatic disruption in routine breast cancer follow-up during the COVID-19 pandemic. Providers and health systems should emphasize reintegrating patients who missed appointments during COVID-19 back into regular surveillance programs to avoid significant morbidity and mortality from missed breast cancer recurrences.<br />Competing Interests: Declaration of competing interest NO is a consultant for Merck and AstraZeneca. There are no additional conflicts of interests to disclose.<br /> (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Subjects :
- Adolescent
Adult
Aged
Breast Neoplasms drug therapy
COVID-19 epidemiology
Cohort Studies
Female
Hospitals, Urban
Humans
Mastectomy
Middle Aged
Neoplasm Recurrence, Local
New York City epidemiology
Pandemics
Retrospective Studies
SARS-CoV-2
Young Adult
Breast Neoplasms mortality
COVID-19 psychology
Cancer Survivors psychology
Survivorship
Subjects
Details
- Language :
- English
- ISSN :
- 1532-3080
- Volume :
- 59
- Database :
- MEDLINE
- Journal :
- Breast (Edinburgh, Scotland)
- Publication Type :
- Academic Journal
- Accession number :
- 34385028
- Full Text :
- https://doi.org/10.1016/j.breast.2021.07.018